Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Mylan Teams Up with Revance Therapeutics to Develop Botox Biosimilar February 28, 2018 ObsEva Fertility Drug Shows Some Promise in Late-Stage Trial February 25, 2018 <b>President Trump's</b> Right-Hand Woman, <b>Kellyanne Conway</b> Consulted for Nation???s Leading Science Group April 2, 2017
<b>President Trump's</b> Right-Hand Woman, <b>Kellyanne Conway</b> Consulted for Nation???s Leading Science Group April 2, 2017
